During our committee’s hearing this week, the physicians discussed the importance of utilizing every possible treatment (FDA EUA indicated and approved US off-label drugs and those approved for COVID-19 in other countries) option to address the needs of individual patients, especially in times of emergency. One treatment highlighted at the hearing was ivermectin, a treatment that won its creator a Nobel Prize in medicine and that is included in the World Health Organization’s “World’s List of Essential Medicines.”[3] Unfortunately, despite a number of new studies, the NIH has not updated its guidelines since August 27, 2020, and state that the “COVID-19 Treatment Guidelines Panel recommends against the use of ivermectin for the treatment of COVID-19, except in a clinical trial.”[4] Separately, a physician and CEO of a pharmaceutical company discussed a widely distributed oral antiviral, favipiravir, which is available in 30 countries, but not the United States.[5]
[-] massimaux | 3 points | Dec 12 2020 17:04:07
During our committee’s hearing this week, the physicians discussed the importance of utilizing every possible treatment (FDA EUA indicated and approved US off-label drugs and those approved for COVID-19 in other countries) option to address the needs of individual patients, especially in times of emergency. One treatment highlighted at the hearing was ivermectin, a treatment that won its creator a Nobel Prize in medicine and that is included in the World Health Organization’s “World’s List of Essential Medicines.”[3] Unfortunately, despite a number of new studies, the NIH has not updated its guidelines since August 27, 2020, and state that the “COVID-19 Treatment Guidelines Panel recommends against the use of ivermectin for the treatment of COVID-19, except in a clinical trial.”[4] Separately, a physician and CEO of a pharmaceutical company discussed a widely distributed oral antiviral, favipiravir, which is available in 30 countries, but not the United States.[5]
permalink